Novo Nordisk Says Global Payer Pressure Limits Price Rises
This article was originally published in Scrip
Executive Summary
Novo Nordisk A/S says the pricing environment for its drugs is getting more difficult globally, not least in the US, but the Danish diabetes fighter hopes the launch of its once-daily, next-generation basal insulin analogue Tresiba (insulin degludec) will help it expand market share there.
You may also be interested in...
Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes
Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.